As the expression of ANXA2 and TTK is up-regulated in clinical tumor specimens, and they are both closely related to high tumor stage and poor prognosis, targeting ANXA2 and TTK may be new therapeutic strategies for ESCC. The gene discussed is TTK; the disease is esophageal squamous cell carcinoma.